Aquestive Therapeutics, Inc. (NASDAQ:AQST) Shares Bought by Millennium Management LLC

Millennium Management LLC increased its holdings in Aquestive Therapeutics, Inc. (NASDAQ:AQST) by 111.2% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 87,227 shares of the company’s stock after buying an additional 45,926 shares during the quarter. Millennium Management LLC owned about 0.10% of Aquestive Therapeutics worth $311,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. New York State Common Retirement Fund grew its stake in shares of Aquestive Therapeutics by 713.3% during the 4th quarter. New York State Common Retirement Fund now owns 12,200 shares of the company’s stock worth $43,000 after purchasing an additional 10,700 shares during the period. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Aquestive Therapeutics during the 4th quarter worth approximately $44,000. PKS Advisory Services LLC acquired a new stake in shares of Aquestive Therapeutics during the 4th quarter worth approximately $63,000. Price T Rowe Associates Inc. MD grew its stake in shares of Aquestive Therapeutics by 16.0% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 27,669 shares of the company’s stock worth $99,000 after purchasing an additional 3,821 shares during the period. Finally, Ancora Advisors LLC grew its stake in shares of Aquestive Therapeutics by 36.5% during the 4th quarter. Ancora Advisors LLC now owns 28,997 shares of the company’s stock worth $103,000 after purchasing an additional 7,751 shares during the period. Institutional investors and hedge funds own 32.45% of the company’s stock.

Aquestive Therapeutics Stock Performance

Shares of AQST stock opened at $3.58 on Wednesday. The stock’s fifty day moving average is $2.71 and its two-hundred day moving average is $3.11. The firm has a market capitalization of $355.59 million, a P/E ratio of -7.96 and a beta of 1.94. Aquestive Therapeutics, Inc. has a fifty-two week low of $2.12 and a fifty-two week high of $5.80.

Aquestive Therapeutics (NASDAQ:AQST) last announced its quarterly earnings data on Monday, May 12th. The company reported ($0.24) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.07). The business had revenue of $8.72 million during the quarter, compared to the consensus estimate of $12.23 million. On average, equities analysts forecast that Aquestive Therapeutics, Inc. will post -0.46 earnings per share for the current year.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on the company. Raymond James set a $7.00 target price on Aquestive Therapeutics in a research report on Friday, March 7th. HC Wainwright reiterated a “buy” rating and set a $10.00 target price on shares of Aquestive Therapeutics in a research report on Thursday, May 15th. Alliance Global Partners reiterated a “buy” rating on shares of Aquestive Therapeutics in a research report on Friday, March 7th. Oppenheimer assumed coverage on Aquestive Therapeutics in a research report on Monday, June 2nd. They set an “outperform” rating and a $7.00 target price on the stock. Finally, Lake Street Capital decreased their target price on Aquestive Therapeutics from $10.00 to $8.00 and set a “buy” rating on the stock in a research report on Friday, March 7th. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $10.14.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.